Drinabant (INN; AVE-1625) is a drug that acts as a selectiveCB1 receptorantagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence.[1][2][3] Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeuticindications of the compound to just appetite suppression. Drinabant reached phase IIbclinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued,[4] likely due to the observation of severe psychiatricside effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawnrimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis.[5]
In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment of (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion of edibles containing large quantities THC and synthetic cannabinoids that are more potent and less expensive than marijuana. Edibles, sold as brownies, cookies and candies, pose particular risks for children, who often consume these by accident. There are currently no approved treatments for ACO.
See also[]
Cannabinoid receptor antagonist
References[]
^Lange JH, Kruse CG (2008). "Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives". The Chemical Record. 8 (3): 156–68. doi:10.1002/tcr.20147. PMID18563799.
^Kwon MO, Herrling P (2005). "List of drugs in development for neurodegenerative diseases. Update September 2005". Neuro-Degenerative Diseases. 2 (2): 61–108. doi:10.1159/000089285. PMID16909049. S2CID2553974.
^Gerald Litwack (14 August 2009). Anandamide. Academic Press. p. 172. ISBN978-0-12-374782-2. Retrieved 13 May 2012.
^Reggio, Patricia H. (2009). "Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists". Drug Development Research. 70 (8): 585–600. doi:10.1002/ddr.20337. ISSN0272-4391. S2CID83478850.